VIVOLTA

𝗢𝘂𝗿 𝗰𝗹𝗶𝗲𝗻𝘁𝘀 𝗸𝗻𝗼𝘄, 𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝟮𝟬 𝗼𝗿 𝟯𝟬 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝘂𝗻 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 𝗶𝘀 𝘂𝘀𝘂𝗮𝗹𝗹𝘆 𝘁𝗵𝗲 𝗲𝗮𝘀𝘆 𝗽𝗮𝗿𝘁. The real test begins during scale-up and process qualification: controlling output across polymer lots, equipment runs, operators, and increasing volumes while maintaining acceptable Cp and Cpk. Electrospinning is notoriously sensitive to raw-material variability and tightly coupled process parameters. Changes in polymer molecular weight, crystallinity, solvent behavior, climate, flow, or electric-field conditions can alter fiber morphology, thickness, porosity, and ultimately device performance. Without a stable, capable, and validated process, clinical and commercial manufacturing is not viable under a medical-device quality system. VIVOLTA was built for this stage. Our team combines extensive electrospinning process-validation experience with proprietary automated production systems designed to control the variables that make nanofiber manufacturing difficult to qualify. Medical-device R&D and procurement teams choose us for the following reasons:  → 𝗢𝗻𝗲 𝗮𝗰𝗰𝗼𝘂𝗻𝘁𝗮𝗯𝗹𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗳𝗿𝗼𝗺 𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝘁𝗼 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 Materials selection, feasibility, product and process development, validation, and manufacturing remain within one integrated program. → 𝗗𝗲𝘃𝗶𝗰𝗲-𝘀𝗽𝗲𝗰𝗶𝗳𝗶𝗰 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 We engineer fiber architecture, mechanics, degradation, porosity, and biological function against the requirements of the finished device—not a catalogue of standard nanofiber materials. → 𝗠𝗲𝗱𝗶𝗰𝗮𝗹-𝗴𝗿𝗮𝗱𝗲 𝘀𝗰𝗮𝗹𝗲-𝘂𝗽 Our automated MediSpin™ platform combines controlled electrospinning with in-line quality systems to support repeatable, high-throughput production. → 𝗜𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝘁𝗲𝗰𝗵𝗻𝗶𝗰𝗮𝗹 𝗱𝗲𝗽𝘁𝗵 Materials scientists, application developers, automation engineers, and manufacturing specialists work as one team. → 𝗔 𝘀𝗶𝗺𝗽𝗹𝗲𝗿 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻 VIVOLTA can manage raw materials and integrate downstream steps such as laser cutting, packaging, and labelling. The result is fewer technical handoffs, clearer ownership, and a more direct route from feasibility to validated production. Our CDMO brochure explains how we apply this model across cardiovascular, orthopaedic, wound-care, soft-tissue, and drug-delivery programs. Ready to get started? Visit our website and contact us today: https://www.vivolta.com/ #MedicalDevices #CDMO #Electrospinning #MedTech

𝗩𝗜𝗩𝗢𝗟𝗧𝗔 𝗶𝘀 𝗲𝘅𝗵𝗶𝗯𝗶𝘁𝗶𝗻𝗴 𝗮𝘁 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝗜𝗿𝗲𝗹𝗮𝗻𝗱 𝟮𝟬𝟮𝟲! 📍 Galway Racecourse 📅 23–24 September 2026 🔎 Stand 336 Register here: https://lnkd.in/enviuUWN We will be there to discuss how medical electrospinning can solve device-interface problems that conventional materials and manufacturing processes still struggle with. Why this is timely: Electrospun medical devices are gaining real clinical and regulatory momentum. A recent example is Solaris Endovascular DE, a drug-eluting covered stent platform incorporating an electrospun PTFE barrier and targeted sirolimus release at the stent edges. The device received FDA Breakthrough Device designation in 2026, with DEScover interim data reporting strong six-month patency performance in dialysis access. For engineers, the signal is clear: electrospinning is no longer just a materials-science concept. It is becoming a practical way to engineer functional biointerfaces with clear clinical performance advantages. That is where VIVOLTA comes in. As a fully integrated medical electrospinning CDMO, we help partners develop, scale, and manufacture electrospun medical products from concept to clinical and commercial supply. At Stand 336, we will focus on four key segments: → 𝗖𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 Low-profile, compliant coverings for stents, grafts, skirts, and tubular constructs. Key engineering targets include water-entry pressure, crimp/expansion durability, conformal substrate bonding, hemocompatibility, sealing, and endothelialization-guided architecture. → 𝗢𝗿𝘁𝗵𝗼𝗽𝗮𝗲𝗱𝗶𝗰𝘀 & 𝘀𝗽𝗼𝗿𝘁𝘀 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 Resorbable collagen, polymer, and bioceramic scaffolds for soft-tissue repair and bony integration. Relevant constraints include porosity, particle loading, mechanical reinforcement, resorption profile, conformability, and biological integration at the repair interface. → 𝗪𝗼𝘂𝗻𝗱 𝗰𝗮𝗿𝗲 Nanofiber matrices designed for cell infiltration, exudate handling, moisture balance, resorption control, and local delivery of antimicrobials, APIs, or biologics. → 𝗗𝗿𝘂𝗴-𝗲𝗹𝘂𝘁𝗶𝗻𝗴 & 𝗯𝗶𝗼𝗮𝗰𝘁𝗶𝘃𝗲 𝗱𝗲𝘃𝗶𝗰𝗲𝘀 Fiber-level control of composition, loading, release kinetics, degradation, thickness, and architecture for localized therapeutic effect. When you visit, bring the hard constraints: fiber diameter distribution, pore architecture, substrate bonding, delamination risk, API loading, burst release, degradation window, inline QC, yield, and scale-up. We will be happy to provide a free consultation on how our medical electrospinning solutions can solve these challenges. #MedicalTechnologyIreland #MedTechIreland #electrospinning #medicaldevices #medtech #biomaterials #CDMO #cardiovascular #orthopaedics #woundcare

🎉🎉Please join us in welcoming Sven Van Heck to Vivolta as our new 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗠𝗮𝗻𝗮𝗴𝗲𝗿! Sven brings a wealth of experience in launching new products and rolling out new processes, that is exactly the kind of expertise that will help us scale smoothly as we grow. What's already clear after just a few days: Sven combines a calm, level-headed approach with genuine engagement. He's been fully present and asking the right questions from day one, and that energy is contagious. 𝗪𝗲𝗹𝗰𝗼𝗺𝗲 𝗮𝗯𝗼𝗮𝗿𝗱, 𝗦𝘃𝗲𝗻! 🚀

📢 Exciting opportunity for 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 P𝗿𝗼𝗳𝗲𝘀𝘀𝗶𝗼𝗻𝗮𝗹𝘀 in MedTech! We're looking for an 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝗱 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 & 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗘𝗻𝗴𝗶𝗻𝗲𝗲𝗿  who doesn't just follow the process, but elevates it! Someone who gets energized by turning complex regulatory requirements into 𝗿𝗼𝗰𝗸-𝘀𝗼𝗹𝗶𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 that actually stick. If you love diving deep into protocols, driving compliance with confidence, and making a real impact in a cutting-edge environment: this one's for you! You'll be joining Vivolta, we are a fast-growing 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗖𝗗𝗠𝗢 in the Eindhoven region, pioneering the development and manufacturing of 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝘂𝗻 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗶𝗺𝗽𝗹𝗮𝗻𝘁𝘀. ➡️ ➡️ Ready to take your validation expertise to the next level? Or do you know someone who would be a perfect fit? Drop us a message, we'd love to connect! 🔗https://lnkd.in/e-ttkQcy

🧠 𝗡𝗲𝘄 𝗮𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗯𝗿𝗶𝗲𝗳: 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝗶𝗻𝗻𝗶𝗻𝗴 𝗳𝗼𝗿 𝗻𝗲𝘂𝗿𝗼𝘀𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗿𝗲𝗽𝗮𝗶𝗿 Neurosurgical repair demands materials that do more than close and protect. Dural substitutes must help provide a reliable barrier against CSF leakage while supporting tissue integration. Nerve repair solutions must protect delicate anatomy while guiding regeneration. That is exactly where electrospinning can bring value. Our new Neurosurgery Application Brief explores how electrospun scaffolds can enable next-generation solutions for: • Dura repair and watertight barrier function • Anti-adhesion barriers after spinal surgery • Nerve wraps and protectors • Nerve guidance conduits • Drug-eluting neuro scaffolds The core idea is simple: move beyond passive materials toward intelligent biointerfaces that can seal, protect, guide, and regenerate. At VIVOLTA, we help medical device innovators translate these concepts into scalable electrospun products — from early feasibility through clinical and commercial manufacturing on our MediSpin™ platform. 📄 Read the new brochure to learn how electrospinning can advance neurosurgical repair. #electrospinning #neurosurgery #medtech #medicaldevices #cdmo

🌟 𝗪𝗲'𝗿𝗲 𝗛𝗶𝗿𝗶𝗻𝗴 𝗮𝘁 𝗩𝗶𝘃𝗼𝗹𝘁𝗮! We are looking for two talented individuals to join our team: 📌 HR Generalist 📌 Executive & Office Administrator Are you someone who thrives in a dynamic environment, loves keeping things organized, and wants to make a real impact? We'd love to hear from you! 📩 Interested? Send your CV and cover letter to jobs@vivolta.com or apply via our website: https://lnkd.in/etgQjuu8 #Hiring #HR #Admin #Vivolta #JobOpening #JoinOurTeam

🎉 𝗪𝗲'𝗿𝗲 𝗲𝘅𝗰𝗶𝘁𝗲𝗱 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 Nils S. 𝘁𝗼 𝘁𝗵𝗲 𝗩𝗶𝘃𝗼𝗹𝘁𝗮 𝘁𝗲𝗮𝗺! Nils joins us as Application Development Technician, bringing a broad background in polymers that will be a great asset to our work. We're looking forward to the expertise, energy, and fresh perspectives Nils brings to the table. Welcome aboard, Nils! 𝗧𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝗵𝗮𝘃𝗲 𝘆𝗼𝘂 𝘄𝗶𝘁𝗵 𝘂𝘀! 🙌

🚀 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝗶𝗻𝗻𝗶𝗻𝗴 𝗶𝘀 𝗲𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝗶𝘁𝘀 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝗶𝗮𝗹 𝗲𝗿𝗮. Recent publications are applying machine learning to predict electrospun fiber-diameter distributions, moving the field closer to data-driven process optimization. At the same time, strategic market activity around electrospun regenerative matrices shows that nanofiber-based medical devices are no longer confined to academic promise. They are becoming clinically relevant, commercially validated technologies. But one question remains central: How do we scale electrospinning without losing the precision that makes it valuable? That is the focus of our white paper: 𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝗶𝗻𝗻𝗶𝗻𝗴: 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗮𝗻𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 In it, we examine the barriers that have historically slowed translation from lab-scale prototypes to medical-grade manufacturing: → 𝗙𝗶𝗯𝗲𝗿 𝗺𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝘆 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 Diameter, alignment, porosity, and surface architecture must be tightly controlled because small variations can affect mechanical performance, drug release, and biological response. → 𝗗𝗶𝗳𝗳𝗶𝗰𝘂𝗹𝘁 𝗯𝗶𝗼𝗺𝗮𝘁𝗲𝗿𝗶𝗮𝗹 𝗳𝗼𝗿𝗺𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀 Natural polymers, collagen blends, bioactive particles, and high-load composites create real formulation and process-stability challenges. → 𝗧𝗵𝗶𝗰𝗸, 𝗽𝗼𝗿𝗼𝘂𝘀 𝟯𝗗 𝘀𝗰𝗮𝗳𝗳𝗼𝗹𝗱𝘀 Many regenerative applications require more than thin sheets. They require volume, architecture, and consistency through the full construct. → 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗮𝘂𝗱𝗶𝘁𝗮𝗯𝗹𝗲 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 Medical electrospinning must be controlled like any other GMP-relevant process: stable environment, repeatable output, in-line monitoring, and quality records that support regulatory expectations. At VIVOLTA, this is where our CDMO model creates value. We help medical device companies translate electrospun product concepts into manufacturable, regulatory-ready solutions — from material selection and formulation development through feasibility, product/process development, scale-up, validation, and clinical or commercial manufacturing. Our vertically integrated capabilities bring materials science, application development, custom engineering, and scalable manufacturing under one roof. The next generation of electrospun medical devices will not be defined by nanofibers alone. It will be defined by the ability to develop, validate, and manufacture those nanofibers — reproducibly, safely, and at commercial scale. 📄 Read our white paper to explore the current challenges of electrospinning and the engineering solutions unlocking its full medical potential: https://lnkd.in/ea-BDNMW #electrospinning #medtech #medicaldevices #biomaterials #cdmo

🩹 𝗪𝗼𝘂𝗻𝗱 𝗰𝗮𝗿𝗲 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴 𝗯𝗲𝘆𝗼𝗻𝗱 𝗽𝗮𝘀𝘀𝗶𝘃𝗲 𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴𝘀. Recent EWMA • European Wound Management Association Conference 2026 headlines made the direction clear: the wound-care community is increasingly focused on technologies that are evidence-led, regenerative, and better equipped to address hard-to-heal wounds. That urgency is justified. 𝗖𝗵𝗿𝗼𝗻𝗶𝗰 𝘄𝗼𝘂𝗻𝗱𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝗮 𝘀𝗶𝗹𝗲𝗻𝘁 𝗲𝗽𝗶𝗱𝗲𝗺𝗶𝗰: 1–2% of people in developed countries suffer from a chronic wound. 1 in 3 chronic wounds fail to heal, even in specialized centers. Biofilms are present in up to 78% of chronic wounds. And the annual cost of chronic wound care in the U.S. has been estimated at $96.8B. At VIVOLTA, we believe the next generation of wound care will be built on biomaterials that do more than cover the wound. Our new wound care brochure shows how electrospinning enables restorative wound care scaffolds with: → 𝗕𝗶𝗼𝗺𝗶𝗺𝗲𝘁𝗶𝗰 𝗮𝗿𝗰𝗵𝗶𝘁𝗲𝗰𝘁𝘂𝗿𝗲 Nanofiber meshes that resemble native extracellular matrix and provide a 3D template for cell attachment, infiltration, and re-epithelialization. → 𝗥𝗲𝘀𝗼𝗿𝗯𝗮𝗯𝗹𝗲 𝗰𝗼𝗺𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝘀 Natural polymers such as collagen, combined with resorbable synthetics, to tune strength, handling, and resorption to the healing cascade. → 𝗧𝘂𝗻𝗮𝗯𝗹𝗲 𝗱𝗿𝘂𝗴 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆 Controlled local release of antimicrobials, growth factors, or other therapeutics directly at the wound site. The clinical and commercial momentum around electrospun wound matrices is no longer theoretical. Market-cleared products are already demonstrating improved closure rates, faster healing, and new pathways for regenerative wound management. The next step is scale. VIVOLTA helps medical device companies develop, scale, and manufacture electrospun wound care scaffolds from concept to clinical and commercial supply — using our fully automated MediSpin™ platform for the consistency, quality, and throughput required by the medical industry. 📄 Read our new wound care brochure to explore how electrospinning can help heal the most challenging wounds. #electrospinning #woundcare #medtech #medicaldevices #cdmo

𝗘𝗹𝗲𝗰𝘁𝗿𝗼𝘀𝗽𝗶𝗻𝗻𝗶𝗻𝗴 𝗶𝘀 𝗺𝗼𝘃𝗶𝗻𝗴 𝗳𝗿𝗼𝗺 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝘁𝗼 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲 𝗶𝗻 𝗰𝗮𝗿𝗱𝗶𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. 𝘛𝘩𝘢𝘵 𝘸𝘢𝘴 𝘰𝘯𝘦 𝘰𝘧 𝘵𝘩𝘦 𝘤𝘭𝘦𝘢𝘳𝘦𝘴𝘵 𝘵𝘢𝘬𝘦𝘢𝘸𝘢𝘺𝘴 𝘧𝘳𝘰𝘮 𝘌𝘶𝘳𝘰𝘗𝘊𝘙 𝘢𝘯𝘥 𝘗𝘊𝘙 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘰𝘳𝘴 𝘋𝘢𝘺 𝘪𝘯 𝘗𝘢𝘳𝘪𝘴 𝘵𝘩𝘪𝘴 𝘸𝘦𝘦𝘬. During the kickoff of PCR Innovators Day, the 𝗜𝗡𝗙𝗟𝗢𝗪 𝗽𝗼𝗹𝘆𝗺𝗲𝗿𝗶𝗰 𝗧𝗔𝗩𝗥 from Innovations for Heart and Vessels Sp. z o.o. was highlighted as a key technology to watch. Its monopartite, electrospun polymeric valve concept is a strong signal that electrospinning is no longer a niche biomaterials process—it is becoming part of the next wave of structural heart innovation. 𝗣𝗲𝗿𝗤𝘀𝗲𝗮𝗹 𝗘𝗹𝗶𝘁𝗲, now part of Haemonetics, also underscored the clinical relevance of resorbable patch-based biomaterial approaches for large-bore vascular closure—sealing the vessel while supporting the body’s own healing response over time. And the 𝗖𝗼𝗔𝗽𝘁 𝗩𝗮𝗹𝘃𝗲𝗧𝗠 from NEOCOR, LLC was another compelling example of where the field is heading: a simple and elegant mitral/tricuspid valve concept using an electrospun polymer valve material to enable flexibility, endothelialization, and an exceptionally low delivery profile. Across the meeting, the same themes kept appearing: 🔹 ultra-low-profile implants 🔹 sutureless polymer attachment to metallic frames 🔹 resorbable scaffolds that support healing and then disappear 🔹 conformal coverings for complex cardiovascular geometries 🔹 biomaterial designs that balance sealing, durability, and endothelialization 𝗙𝗼𝗿 𝗩𝗜𝗩𝗢𝗟𝗧𝗔, 𝘁𝗵𝗶𝘀 𝗺𝗼𝗺𝗲𝗻𝘁𝘂𝗺 𝗶𝘀 𝘀𝗼𝗺𝗲𝘁𝗵𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝗳𝘂𝗲𝗹𝘀 𝗼𝘂𝗿 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗲𝘃𝗲𝗿𝘆 𝗱𝗮𝘆. As a medical electrospinning CDMO, we see growing demand for exactly these types of cardiovascular solutions: low-profile, conformal, PFAS-free electrospun coverings and scaffolds that can be engineered for sealing, healing, hemocompatibility, crimp durability, and scalable manufacturing. The clinical and commercial direction is becoming clear: next-generation cardiovascular implants will need more than mechanical performance alone. They will need biomaterials that interact intelligently with the body. That is where electrospinning can make a decisive difference. 𝗔 𝘀𝘁𝗿𝗼𝗻𝗴 𝘄𝗲𝗲𝗸 𝗶𝗻 𝗣𝗮𝗿𝗶𝘀—𝗮𝗻𝗱 𝗮 𝘀𝘁𝗿𝗼𝗻𝗴 𝘀𝗶𝗴𝗻𝗮𝗹 𝗳𝗼𝗿 𝘄𝗵𝗮𝘁 𝗰𝗼𝗺𝗲𝘀 𝗻𝗲𝘅𝘁 𝗶𝗻 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗵𝗲𝗮𝗿𝘁 𝗮𝗻𝗱 𝗲𝗻𝗱𝗼𝘃𝗮𝘀𝗰𝘂𝗹𝗮𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻. #EuroPCR #electrospinning #medtech #structuralheart #cardiovascular #medicaldevices #CDMO #biomaterials #TAVR #innovation